🇺🇸 FDA
Patent

US 9585878

Treatment of BDNF-related disorders using laquinimod

granted A61KA61K31/138A61K31/428

Quick answer

US patent 9585878 (Treatment of BDNF-related disorders using laquinimod) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/138, A61K31/428, A61K31/4704, A61K9/0053